Romain Teinturier
Head of operations ERBC Group.
Seminars
Wednesday 3rd December 2025
Rethink In Vivo Oncology Screening: Rapid. Relevant. Responsible
5:30 pm
ERBC Lyon de-risks novel oncology candidates with our pioneering AVI-tumor platform to empower biotech and pharma partners:
- Generate clinically relevant efficacy data in days, not months, adhering to the highest 3R standards
- Utilize a unique immunocompetent avian embryo model to evaluate immunotherapies in a biologically relevant context
- Accelerate early decision-making for diverse lead candidates, from antibodies and peptides to cell therapies
